(Press-News.org) CHICAGO – A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell therapy in nearly two-thirds of patients. While survival data is still accumulating, several patients lived 12 months or longer after receiving the investigational therapy, which is notable given the typical survival for this patient population is less than a year.
The findings were presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 102) and simultaneously published in Nature Medicine by researchers from the Abramson Cancer Center (ACC) of the University of Pennsylvania and Penn’s Perelman School of Medicine.
The results build on the hopeful momentum of an early report from the same phase I clinical trial published last year, alongside similar findings from other researchers across the United States. Glioblastoma (GBM) is the most common—and deadly—brain cancer in adults, with average life expectancies of 12-18 months after diagnosis, despite decades of focused research efforts. Even after aggressive treatment, the cancer grows back, or recurs, in nearly all patients. The median survival rate for recurrent GBM typically ranges from 6 to 10 months.
“Seeing recurrent GBM tumors shrink like this is extraordinary because the immunotherapy drugs that we’ve tried in the past have been unable to do that,” said principal investigator Stephen Bagley, MD, MSCE, an assistant professor of Hematology-Oncology, and Neurosurgery. “Before the trial, many of these patients had tumors that were growing rapidly, and the treatment changed the trajectory of their disease, which is very meaningful to patients with GBM.”
Penn-developed dual-target CAR
CAR T cell therapy is a form of personalized immunotherapy that uses a patient’s own immune cells to treat their cancer. While widely successful in blood cancers, CAR T cell therapy has yet to make significant inroads against solid tumor cancers, like brain cancer.
The Penn-developed CAR T product used in this study is unique in that it targets not one, but two proteins commonly found in brain tumors—epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Rα2)—and is administered through an injection into the cerebrospinal fluid. The dual-target CAR was created in the laboratory of Donald M. O’Rourke, MD, the John Templeton, Jr., MD Professor in Neurosurgery and director of the Glioblastoma Translational Center of Excellence in the Abramson Cancer Center at Penn Medicine, who was scientific advisor to the trial.
Temporary decrease in tumor size in most patients
The study enrolled 18 patients with recurrent GBM who underwent surgery to remove as much of the tumor as possible, followed by infusion of the dual-target CAR T cell therapy directly into the cerebrospinal fluid. The tumors became smaller after CAR T cell therapy in eight of the 13 patients (62 percent) who still had at least 1cm of tumor remaining after surgery. While the tumors grew back after one to three months in most patients, there were encouraging signals:
Two patients (11 percent) remain alive with stable disease that has continued beyond six months.
Of the seven patients with at least 12 months’ follow-up time, three (43 percent) were still alive after a year.
This includes one individual whose cancer has remained stable, with no tumor growth for more than 16 months, despite advanced disease spread and rapid growth at the time of enrollment.
The researchers also found signs that the therapy remains in the immune system after the infusion to prevent tumor growth over time. In one patient who underwent surgery again due to tumor regrowth after the CAR T cell therapy, the researchers detected positive effects of the treatment in the removed tissue. These effects included infiltration of T cells throughout the tumor and clearance of the tumor by immune cells called macrophages. The researchers were able to see similar signals of the therapy stimulating the immune system through spinal fluid samples from the other patients, including one patient whose spinal fluid still had detectable CAR T cells one year after receiving the treatment.
“These results reaffirm that we’re onto something with our dual target therapy, and that we have a good template that we can begin refining for even better outcomes,” O’Rourke said. “Periods of stability, when tumors shrink or don’t grow, vastly improve the quality of a patient’s life. Our goal is to refine the treatment so that more patients experience longer-lasting results.”
In the final cohort of this study, the team plans to give patients more than one dose of the CAR T cell therapy, to see if repeat dosing extends the time before the tumors grow back.
With safety established, next clinical trials to open soon
Ten of 18 patients (56 percent) experienced grade 3 neurotoxicity, with no new or unexpected side effects reported, beyond the known side effects of other FDA-approved CAR T cell therapies. The neurotoxicity was managed successfully, and the therapy was determined to be safe and feasible.
Based on these results, the researchers determined the maximum tolerated dose level to carry forward in upcoming clinical trials, the first of which will be for patients with newly diagnosed GBM. See study info and enrollment contacts here.
“By the time GBM recurs, it has become even more challenging to treat, and the patient has already been through a lot,” Bagley said. “We’re hopeful that by moving quickly to test this CAR T cell therapy in the newly diagnosed setting, the cancer will be more vulnerable to therapy and more patients will see a benefit.”
This study was funded by Kite, a Gilead Company, the Abramson Cancer Center Glioblastoma Translational Center of Excellence, the Templeton Family Initiative in Neuro-Oncology, and the Maria and Gabriele Troiano Brain Cancer Immunotherapy Fund.
Information for patients interested in joining a clinical trial: visit Penn Medicine's Abramson Cancer Center Clinical Trial Information Service online or call 1-855-216-0098 to speak to a clinical trial navigator.
Editor’s note: O’Rourke is an inventor on multiple patents related to CAR T cell therapy in solid tumors that have been licensed by the University of Pennsylvania and has received royalties from these license agreements. O’Rourke is a paid consultant for Kite Pharma. Penn has received and may receive in the future, sponsored research funding and certain intellectual property license-related payments from Kite Pharma.
###
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $580 million awarded in the 2023 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Doylestown Health, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.9 billion enterprise powered by nearly 49,000 talented faculty and staff.
END
Dual-target CAR T cell therapy slows growth of aggressive brain cancer
Phase I clinical trial results demonstrate encouraging tumor reductions rarely seen in recurrent glioblastoma
2025-06-01
ELSE PRESS RELEASES FROM THIS DATE:
Adding immune checkpoint inhibitor to standard chemotherapy regimen improves outcomes in stage 3 colon cancer, study finds
2025-06-01
BOSTON, June 1, 2025 – Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.
These results stem from the ATOMIC trial, a phase 3 multicenter, randomized, ...
Diet influences survival after stage iii colon cancer, Dana-Farber study finds
2025-06-01
BOSTON, June 1, 2025 – Patients with colon cancer who consumed an anti-inflammatory diet during a phase 3 clinical trial showed longer overall survival post-treatment compared to those on a proinflammatory diet, according to a Dana-Farber Cancer Institute analysis. Engaging in higher levels of physical activity may amplify the positive influence on survival.
“One of the most common questions that patients ask is what they should do after treatment to maximally reduce their risk of cancer recurrence and improve survival,” says first author Dr. Sara Char, a clinical fellow in Hematology and Oncology at Dana-Farber ...
Switch to experimental drug after liquid biopsy detection of breast cancer recurrence improves outcomes
2025-06-01
A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.
The SERENA-6 study, published June 1 in the New England Journal of Medicine and presented concurrently at the annual meeting of the American Society for Clinical Oncology, was conducted at multiple medical centers, principally in Europe, East Asia and the United States, including at Weill ...
Alliance presents results from phase III ATOMIC trial combining atezolizumab with chemotherapy for patients with stage III dMMR colon cancer at ASCO 2025
2025-06-01
June 1, 2025 — The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The study, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, met its primary endpoint, demonstrating a statistically ...
Immunotherapy boosts chemotherapy in combating stage 3 colon cancer
2025-06-01
Late-breaking abstract featured at ASCO 2025
ROCHESTER, Minn. — Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.
Now, new research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer — and with a specific ...
AI deciphers plant DNA: language models set to transform genomics and agriculture
2025-06-01
By leveraging the structural parallels between genomic sequences and natural language, these AI-driven models can decode complex genetic information, offering unprecedented insights into plant biology. This advancement holds promise for accelerating crop improvement, enhancing biodiversity conservation, and bolstering food security in the face of global challenges.
Traditionally, plant genomics has grappled with the intricacies of vast and complex datasets, often limited by the specificity of traditional machine learning models and the scarcity of annotated ...
Endophytic fungi from halophyte Sesuvium portulacastrum enhance maize growth and salt tolerance
2025-06-01
This research provides key insights into how microbial inoculants can offer a cost-effective, eco-friendly strategy to enhance crop resilience in saline soils.
Soil salinization is a major global challenge that severely impacts agricultural productivity, with over 3% of the Earth’s terrestrial surface affected. It threatens food security by causing osmotic, ionic, and oxidative stress, which can reduce crop yields by more than 50%. Traditional remediation methods, such as physical and chemical interventions, are often prohibitively expensive. However, ...
Quality of kids’ diets linked with dad’s eating habits as a teen
2025-05-31
While moms have traditionally gotten much of the focus when it comes to children’s eating habits, a new study highlights the importance of dads in shaping a child’s relationship with food. According to the study, young children were more likely to consume the recommended amount of fruits and vegetables if their father ate a healthier diet during his teen years.
The study is based on data from 669 men who answered questionnaires about their eating habits during adolescence and then, years later, provided information about their attitudes and behaviors surrounding their children’s diet.
“Our ...
Alliance trial shows dual immunotherapy improves progression-free survival in advanced squamous cell skin cancer
2025-05-31
May 31, 2025 — A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC). The results, presented as an oral abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, and published in the Journal of Clinical Oncology, suggest a promising new approach for patients with this aggressive form of skin cancer.
“These results show that combining immune checkpoint inhibition targeting the PD-1: PD-L1 pathway ...
Insights from immunotherapy trial inform new approaches to treating advanced skin cancer
2025-05-31
In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.
“It is both an honor and humbling to develop clinical trials ...
LAST 30 PRESS RELEASES:
Eating rate has sustained effects on energy intake from ultra-processed diets, new study reveals
Rise in expectant mothers in UK with autoimmune diseases since millennium
Majority of riders and drivers in UK 'gig economy' suffer anxiety over ratings and pay, study suggests
Virginia Tech researchers develop recyclable, healable electronics
Cognitive outcomes similar after noncardiac surgery whether perioperative hypotension- or hypertension-avoidance strategies employed
Research spotlight: regional disparities in opioid overdose mortality persist despite national decline
Fighting myeloma with fiber: Plant-based diet offers promise
What makes someone leave a Medicare Advantage plan?
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
Advancing personalized medicine through pharmacogenomics: Insights from Ochsner Health
Researchers tested an asthma drug for treating alcoholism. It failed except with this group
Set it and forget it: Autonomous structures can be programmed to jump days in advance
Iron from coal, steel industries alters North Pacific ecosystem
Canadian researcher receives funding from ARIA to unlock potential of plants
Visionary support from Veale Foundation will establish university hospitals Veale Healthcare Transformation Institute
Investigating cocaine addiction using fruit flies
Fruit flies on cocaine could reveal better therapies for addiction
New data shows MMR vaccination rate decline across US
Clinical validation of a circulating tumor DNA–based blood test to screen for colorectal cancer
Screening colonoscopy yields among adults ages 45 to 49 after lowering the colon cancer screening age
Trends in county-level MMR vaccination coverage in children in the United States
Brewed for longevity: drinking coffee linked with healthy aging in women
Researchers find early driver of prostate cancer aggressiveness
Insect protein blocks bacterial infection
New study casts doubt on the likelihood of a Milky Way – Andromeda collision
Prevalence of artificial sweetener neotame in U.S.-marketed disposable e-cigarettes
E-cigarette warnings lower vaping interest and raise quit intentions
Record high: Study finds growing cannabis use among older adults
Trends in past-month cannabis use among older adults
How to create aqueous 100 nm-sized materials with polycavities
[Press-News.org] Dual-target CAR T cell therapy slows growth of aggressive brain cancerPhase I clinical trial results demonstrate encouraging tumor reductions rarely seen in recurrent glioblastoma